JP2014534207A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534207A5
JP2014534207A5 JP2014537287A JP2014537287A JP2014534207A5 JP 2014534207 A5 JP2014534207 A5 JP 2014534207A5 JP 2014537287 A JP2014537287 A JP 2014537287A JP 2014537287 A JP2014537287 A JP 2014537287A JP 2014534207 A5 JP2014534207 A5 JP 2014534207A5
Authority
JP
Japan
Prior art keywords
car
seq
amino acid
acid sequence
domain comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537287A
Other languages
English (en)
Other versions
JP2014534207A (ja
JP6267644B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061025 external-priority patent/WO2013059593A1/en
Publication of JP2014534207A publication Critical patent/JP2014534207A/ja
Publication of JP2014534207A5 publication Critical patent/JP2014534207A5/ja
Application granted granted Critical
Publication of JP6267644B2 publication Critical patent/JP6267644B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (24)

  1. a)HA22の抗原結合ドメイン、膜貫通ドメイン、及び細胞内T細胞シグナル伝達ドメイン;又は、
    b)BL22の抗原結合ドメイン、膜貫通ドメイン、並びにi)CD28及び/若しくはii)CD137を含む細胞内T細胞シグナル伝達ドメイン、
    を含むキメラ抗原受容体(CAR)。
  2. 抗原結合ドメインが、配列番号1又は2を含むアミノ酸配列を含む軽鎖可変領域を含む、請求項1に記載のCAR。
  3. 抗原結合ドメインが、配列番号3又は4を含むアミノ酸配列を含む重鎖可変領域を含む、請求項1又は2に記載のCAR。
  4. 抗原結合ドメインが、配列番号5又は6を含むアミノ酸配列を含む、請求項1〜3のいずれか1項に記載のCAR。
  5. 配列番号7を含むリーダー配列をさらに含む、請求項1〜4のいずれか1項に記載のCAR。
  6. 免疫グロブリンドメインをさらに含む、請求項1〜5のいずれか1項に記載のCAR。
  7. 免疫グロブリンドメインが、配列番号8、9又は36を含むアミノ酸配列を含む、請求項6に記載のCAR。
  8. 膜貫通ドメインがi)CD8及び/又はii)CD28を含む、請求項1〜7のいずれか1項に記載のCAR。
  9. 膜貫通ドメインが、(a)配列番号10若しくは33を含むCD8アミノ酸配列、及び/又は(b)配列番号11を含むCD28アミノ酸配列を含む、請求項1〜8のいずれか1項に記載のCAR。
  10. 細胞内T細胞シグナル伝達ドメインが、i)CD28、ii)CD137、及びiii)CD3ζのうち1つ以上を含む、請求項1〜9のいずれか1項に記載のCAR。
  11. 細胞内T細胞シグナル伝達ドメインが、配列番号12を含むCD28アミノ酸配列を含む、請求項1〜10のいずれか1項に記載のCAR。
  12. 細胞内T細胞シグナル伝達ドメインが、配列番号13又は34を含むCD137アミノ酸配列を含む、請求項1〜11のいずれか1項に記載のCAR。
  13. 細胞内T細胞シグナル伝達ドメインが、配列番号14又は35を含むCD3ζアミノ酸配列を含む、請求項1〜12のいずれか1項に記載のCAR。
  14. 配列番号15〜20及び32のいずれか1つを含むアミノ酸配列を含む、請求項1〜10のいずれか1項に記載のCAR。
  15. 請求項1〜14のいずれか1項に記載のCARをコードするヌクレオチド配列を含む核酸。
  16. 配列番号21〜23及び38からなる群より選択されるヌクレオチド配列を含む、請求項15に記載の核酸。
  17. 配列番号24〜25及び39からなる群より選択されるヌクレオチド配列をさらに含む、請求項16に記載の核酸。
  18. 請求項15〜17のいずれか1項に記載の核酸を含む組換え発現ベクター。
  19. 請求項18に記載の組換え発現ベクターを含む、単離された宿主細胞。
  20. 請求項19に記載の宿主細胞を少なくとも1つ含む、細胞集団。
  21. 請求項1〜14のいずれか1項に記載のCARと特異的に結合する、抗体又はその抗原結合部分。
  22. 請求項1〜14のいずれか1項に記載のCAR、請求項15〜17のいずれか1項に記載の核酸、請求項18に記載の組換え発現ベクター、請求項19に記載の宿主細胞、請求項20に記載の細胞集団、又は請求項21に記載の抗体若しくはその抗原結合部分と、医薬上許容される担体とを含む、医薬組成物。
  23. (a)哺乳動物由来の1つ以上の細胞を含むサンプルを、請求項1〜14のいずれか1項に記載のCAR、請求項15〜17のいずれか1項に記載の核酸、請求項18に記載の組換え発現ベクター、請求項19に記載の宿主細胞、請求項20に記載の細胞集団、又は請求項21に記載の抗体若しくはその抗原結合部分と接触させることによって、複合体を形成する工程、及び
    (b)複合体を検出する工程であって、該複合体の検出が哺乳動物におけるがんの存在を示す工程、
    を含む哺乳動物におけるがんの存在を検出する方法。
  24. 哺乳動物におけるがん治療又は予防するための、請求項1〜14のいずれか1項に記載のCAR、請求項15〜17のいずれか1項に記載の核酸、請求項18に記載の組換え発現ベクター、請求項19に記載の宿主細胞、請求項20に記載の細胞集団、請求項21に記載の抗体若しくはその抗原結合部分、又は請求項22に記載の医薬組成物。
JP2014537287A 2011-10-20 2012-10-19 抗cd22キメラ抗原受容体 Expired - Fee Related JP6267644B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549516P 2011-10-20 2011-10-20
US61/549,516 2011-10-20
PCT/US2012/061025 WO2013059593A1 (en) 2011-10-20 2012-10-19 Anti-cd22 chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017132749A Division JP2017212996A (ja) 2011-10-20 2017-07-06 抗cd22キメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2014534207A JP2014534207A (ja) 2014-12-18
JP2014534207A5 true JP2014534207A5 (ja) 2015-12-03
JP6267644B2 JP6267644B2 (ja) 2018-01-24

Family

ID=47143305

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014537287A Expired - Fee Related JP6267644B2 (ja) 2011-10-20 2012-10-19 抗cd22キメラ抗原受容体
JP2017132749A Pending JP2017212996A (ja) 2011-10-20 2017-07-06 抗cd22キメラ抗原受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017132749A Pending JP2017212996A (ja) 2011-10-20 2017-07-06 抗cd22キメラ抗原受容体

Country Status (11)

Country Link
US (1) US9868774B2 (ja)
EP (1) EP2768863B1 (ja)
JP (2) JP6267644B2 (ja)
CN (2) CN109485730A (ja)
AU (2) AU2012325915A1 (ja)
BR (1) BR112014008849A2 (ja)
CA (1) CA2851795C (ja)
ES (1) ES2654060T3 (ja)
IN (1) IN2014CN02906A (ja)
RU (1) RU2644243C2 (ja)
WO (1) WO2013059593A1 (ja)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021026173B1 (pt) 2010-12-09 2023-12-05 The Trustees Of The University Of Pennsylvania Composição farmacêutica
BR112014008849A2 (pt) * 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
EP3279315A3 (en) 2012-05-25 2018-02-28 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
WO2014065961A1 (en) * 2012-10-24 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP3626741A1 (en) 2013-02-20 2020-03-25 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
EP3623380A1 (en) 2013-03-15 2020-03-18 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
BR112016004095A2 (pt) 2013-08-30 2017-10-17 Univ Texas administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
JP6502931B2 (ja) 2013-10-11 2019-04-17 アメリカ合衆国 Tem8抗体およびその使用
EP3066118B1 (en) * 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN103589742A (zh) * 2013-11-07 2014-02-19 申峰 嵌合体抗原受体胞内段的基因及其编码蛋白
JPWO2015068847A1 (ja) * 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
CA2930587A1 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CN106279434B (zh) * 2014-02-24 2020-07-03 西比曼生物科技(上海)有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
PL3129470T3 (pl) 2014-04-07 2021-11-29 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
CN106574246A (zh) * 2014-04-10 2017-04-19 西雅图儿童医院(Dba西雅图儿童研究所) 用于细胞免疫治疗的方法和组合物
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
KR102594343B1 (ko) 2014-07-21 2023-10-26 노파르티스 아게 Cd33 키메라 항원 수용체를 사용한 암의 치료
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
MX2017001013A (es) 2014-07-21 2018-02-21 Novartis Ag Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
PT3183268T (pt) 2014-08-19 2020-05-15 Novartis Ag Recetor de antigénio quimérico (car) anti-cd123 para uso no tratamento de cancro
US9975959B2 (en) 2014-08-29 2018-05-22 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
JP6810685B2 (ja) 2014-09-04 2021-01-06 セレクティスCellectis 癌免疫療法のための栄養膜糖タンパク質(5t4、tpbg)特異的キメラ抗原受容体
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2961609C (en) 2014-09-17 2023-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
US10570186B2 (en) 2014-11-05 2020-02-25 Board Of Regents, The University Of Texas System Chimeric antigen receptors (CAR) to selectively target protein complexes
EP3536707A1 (en) 2014-11-05 2019-09-11 Board of Regents, The University of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
US10689456B2 (en) * 2014-12-08 2020-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD70 chimeric antigen receptors
CN107002045A (zh) 2014-12-24 2017-08-01 Ucl商务股份有限公司 细胞
KR20170093254A (ko) 2014-12-29 2017-08-14 노파르티스 아게 키메라 항원 수용체-발현 세포를 제조하는 방법
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
KR20170135824A (ko) 2015-01-26 2017-12-08 셀렉티스 출아형 원형질 세포의 수지상 세포 신생물 또는 재발된/난치성 급성 골수성 림프종의 치료를 위한 cd123에 결합하는 키메라 항원 수용체들을 지닌 것으로 여겨지는, t 세포 수용체 넉 아웃 조작된 면역 세포들
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
US20190388469A1 (en) 2015-01-30 2019-12-26 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
WO2016149578A1 (en) 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
WO2016154003A1 (en) 2015-03-20 2016-09-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to gp120 and their use
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
CN113502270A (zh) 2015-06-10 2021-10-15 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
CN115925971A (zh) 2015-06-19 2023-04-07 塞巴斯蒂安·科博尔德 Pd-1-cd28融合蛋白及其在医学中的用途
WO2016210447A1 (en) 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
US11098283B2 (en) 2015-08-25 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-Myb
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
WO2017044699A1 (en) * 2015-09-10 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 chimeric antigen receptors
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
US11723922B2 (en) 2015-10-16 2023-08-15 Ludwig-Maximilians-Universität München CXCR6-transduced T cells for targeted tumor therapy
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
EP3423483A4 (en) 2016-03-02 2019-08-21 Board Of Regents Of the University Of Texas System VARIANTS OF HUMAN ENZYME KYNURENINASE HAVING IMPROVED PHARMACOLOGICAL PROPERTIES
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
CN105968210B (zh) * 2016-05-13 2019-05-31 深圳生创精准医疗科技有限公司 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
CN106167527A (zh) * 2016-06-13 2016-11-30 长沙郝怡雅医药科技有限公司 一种融合蛋白
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
KR20190025855A (ko) 2016-06-30 2019-03-12 에프. 호프만-라 로슈 아게 개선된 입양 t-세포 요법
JP6908710B2 (ja) 2016-09-21 2021-07-28 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ ケモカイン受容体ccr4を標的にするキメラ抗原受容体(car)およびその使用
WO2018057447A1 (en) 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
AU2017336094A1 (en) 2016-09-29 2019-04-18 Immunitybio, Inc. HLA class I-deficient NK-92 cells with decreased immunogenicity
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
CN110381963A (zh) 2016-10-13 2019-10-25 朱诺治疗学股份有限公司 涉及色氨酸代谢途径调节剂的免疫治疗方法和组合物
CN109983027A (zh) 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体
CN107964549B (zh) * 2016-10-20 2020-12-08 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
WO2018111981A1 (en) 2016-12-13 2018-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
JP7118072B2 (ja) 2017-01-06 2022-08-15 イミュニティーバイオ インコーポレイテッド Cd96/tigit発現が低下した遺伝子改変型nk-92細胞
JP6706394B1 (ja) * 2017-01-09 2020-06-03 レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. 抗メソセリン免疫療法によりがんを処置するための組成物および方法
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110612119A (zh) 2017-02-07 2019-12-24 西雅图儿童医院(Dba西雅图儿童研究所) 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
EA201992232A1 (ru) 2017-03-22 2020-05-14 Новартис Аг Композиции и способы для иммуноонкологии
CN116874608A (zh) * 2017-03-27 2023-10-13 诺伊尓免疫生物科技株式会社 嵌合抗原受体
EP3592380A1 (en) 2017-03-31 2020-01-15 Cellectis New universal chimeric antigen receptor t cells specific for cd22
CN110582280B (zh) 2017-03-31 2024-03-19 小利兰·斯坦福大学托管委员会 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法
CA3059643A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
WO2018219278A1 (en) * 2017-06-01 2018-12-06 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cell preparation and uses thereof
US11883431B2 (en) 2017-06-05 2024-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T-cells modified to overexpress PHF19
JP2020524992A (ja) * 2017-06-22 2020-08-27 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体操作ナチュラルキラー細胞を化学療法薬物担体として使用する組み合わせがん療法
WO2019002633A1 (en) 2017-06-30 2019-01-03 Cellectis CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
JP2020535128A (ja) 2017-09-19 2020-12-03 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体t細胞治療のための組成物およびその使用
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
WO2019079249A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
AU2018352984B2 (en) * 2017-10-18 2024-02-01 Precigen, Inc. Polypeptide compositions comprising spacers
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
US11661439B2 (en) 2017-12-17 2023-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels and use thereof
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
CN111670246A (zh) 2018-01-31 2020-09-15 南克维斯特公司 5%人白蛋白在洗涤和收获培养基中的用途
US20210052647A1 (en) 2018-02-09 2021-02-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
AU2019231205A1 (en) * 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
US11813292B2 (en) 2018-03-12 2023-11-14 Immunity Bio, Inc. Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)
CN112218644A (zh) 2018-04-16 2021-01-12 得克萨斯州大学系统董事会 人类犬尿氨酸酶及其用途
CA3097858A1 (en) 2018-04-24 2019-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
DK3797155T3 (da) 2018-05-22 2022-08-29 Immunitybio Inc Optimering af nk-92-cellevækst ved hjælp af poloxamer
KR20240001720A (ko) * 2018-05-22 2024-01-03 난트퀘스트, 인크. Fc-엡실론 car
WO2019226521A1 (en) 2018-05-22 2019-11-28 Nantkwest, Inc. Basal media for growing nk-92 cells
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
CA3105601C (en) 2018-07-10 2024-01-16 Nantkwest, Inc. Generating cik nkt cells from cord blood
US20210267190A1 (en) 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
CA3105694A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
US20210324042A1 (en) 2018-08-01 2021-10-21 Nantkwest, Inc. Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
KR102653878B1 (ko) 2018-08-01 2024-04-01 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 (a quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies)
WO2020028654A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
CN109022363A (zh) * 2018-08-15 2018-12-18 马晓冬 一种基于PiggyBac载体的CD-133-CAR-T系统构建方法
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
BR112021007690A2 (pt) 2018-10-22 2021-08-10 Shanghai GenBase Biotechnology Co., Ltd. anticorpo anti-cldn18.2 e uso do mesmo
KR102569842B1 (ko) 2018-11-06 2023-08-23 난트퀘스트, 인크. 키메라 항원 수용체-변형된 nk-92 세포
CN113164521A (zh) 2018-11-26 2021-07-23 免疫生物公司 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
EP3670530A1 (en) 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CA3128971A1 (en) 2019-03-08 2020-09-17 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
US20220347222A1 (en) 2019-06-24 2022-11-03 The Regents Of The University Of California BCL11B Overexpression to Enhance Human Thymopoiesis and T Cell Function
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質-金属水酸化物錯体およびその方法
AU2020299382A1 (en) 2019-07-02 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind EGFRvIII and their use
JP2022547154A (ja) 2019-09-10 2022-11-10 オブシディアン セラピューティクス, インコーポレイテッド 調節可能な制御のためのca2-il15融合タンパク質
JP2023501871A (ja) 2019-09-20 2023-01-20 上海吉倍生物技術有限公司 Bcma標的化抗体及びキメラ抗原受容体
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー NPM1c陽性がんの免疫療法のための組成物および方法
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for producing engineered memory-like nk cells and preparations containing them
CN115397866A (zh) 2020-03-31 2022-11-25 中外制药株式会社 靶向dll3的多特异性抗原结合分子及其用途
EP4130040A1 (en) * 2020-04-02 2023-02-08 Nanjing Iaso Biotherapeutics Co., Ltd. Fully human anti-human cd22 chimeric antigen receptor and application thereof
CN111484562B (zh) * 2020-04-25 2021-08-20 首都医科大学附属北京朝阳医院 一种靶向cd22蛋白的抗体、嵌合抗原受体和药物
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021240240A1 (en) 2020-05-27 2021-12-02 Antion Biosciences Sa Adapter molecules to re-direct car t cells to an antigen of interest
CA3191211A1 (en) 2020-09-08 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
JP2024512337A (ja) 2021-03-05 2024-03-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗cldn6抗体およびその使用
WO2022251070A1 (en) * 2021-05-27 2022-12-01 Innovative Cellular Therapeutics Holdings, Ltd. Modified chimeric antigen receptor and use thereof
WO2023021113A1 (en) 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023130040A2 (en) 2021-12-31 2023-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
US20240010742A1 (en) 2022-06-10 2024-01-11 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (ja) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO1998041641A1 (en) 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
CA2398136A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
ATE338124T1 (de) * 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
WO2005052006A2 (en) 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
JP2008543839A (ja) * 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
EP3006457B1 (en) 2005-07-29 2017-11-22 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
PT2197903E (pt) 2007-09-04 2015-01-02 Us Gov Health & Human Serv Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2011032022A1 (en) 2009-09-11 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Improved pseudomonas exotoxin a with reduced immunogenicity
WO2011041093A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
BR122021026173B1 (pt) 2010-12-09 2023-12-05 The Trustees Of The University Of Pennsylvania Composição farmacêutica
BR112014008849A2 (pt) * 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22

Similar Documents

Publication Publication Date Title
JP2014534207A5 (ja)
JP2016502512A5 (ja)
RU2014118555A (ru) Химерные антигенные рецепторы к cd22
JP2018505139A5 (ja)
JP2012143232A5 (ja)
JP2018529380A5 (ja)
JP2016026303A5 (ja)
AR077594A1 (es) Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
RU2016124670A (ru) Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
EP4282878A3 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
BR112015009003A2 (pt) receptores de antígeno quiméricos
RU2022102250A (ru) Клетка
RU2017105515A (ru) Сигнальная система
JP2017513478A5 (ja)
Chen et al. Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma
JP2017114866A5 (ja)
RU2017111298A (ru) Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2
JP2017535284A5 (ja)
JP2019527041A5 (ja)
JP2018522564A5 (ja)
JP2018504459A5 (ja)
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
JP2018528786A5 (ja)
JP2015535691A5 (ja)
JP2015535816A5 (ja)